Foghorn Therapeutics Inc. Revenue
Foghorn Therapeutics Inc. (FHTX) reported Revenue of $16.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Foghorn Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $16.07M, a 112.68% increase year-over-year.
- Foghorn Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $3.27M, a 45.11% decline year-over-year.
- Foghorn Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $9.25M, a 223.77% increase year-over-year.
- Foghorn Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $8.15M, a 4.42% increase year-over-year.
- Foghorn Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $30.91M, a 36.75% increase from fiscal 2024.
- Foghorn Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $22.60M, a 33.83% decline from fiscal 2023.
- Foghorn Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $34.16M, a 77.63% increase from fiscal 2022.
- Foghorn Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $19.23M, a 1357.77% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.07M 10-Q · filed 2026-08-06 | $19.34M 10-Q · filed 2026-08-06 | $28.59M derived: sum of 3 quarters · filed 2026-08-06 | $36.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.27M 10-Q · filed 2026-05-07 | $12.51M derived: sum of 2 quarters · filed 2026-05-07 | $20.67M derived: sum of 3 quarters · filed 2026-05-07 | $28.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $17.40M derived: sum of 2 quarters · filed 2026-03-11 | $24.96M derived: sum of 3 quarters · filed 2026-08-06 | $30.91M 10-K · filed 2026-03-11 |
| 2025-09-30 | $8.15M 10-Q · filed 2025-11-05 | $15.71M derived: sum of 2 quarters · filed 2026-08-06 | $21.66M 10-Q · filed 2025-11-05 | $24.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.56M 10-Q · filed 2026-08-06 | $13.51M 10-Q · filed 2026-08-06 | $16.36M derived: sum of 3 quarters · filed 2026-08-06 | $24.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.95M 10-Q · filed 2026-05-07 | $8.81M derived: sum of 2 quarters · filed 2026-05-07 | $16.62M derived: sum of 3 quarters · filed 2026-05-07 | $23.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $10.66M derived: sum of 2 quarters · filed 2026-03-11 | $17.55M derived: sum of 3 quarters · filed 2026-03-11 | $22.60M 10-K · filed 2026-03-11 |
| 2024-09-30 | $7.81M 10-Q · filed 2025-11-05 | $14.70M derived: sum of 2 quarters · filed 2025-11-05 | $19.75M 10-Q · filed 2025-11-05 | $25.52M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $6.89M 10-Q · filed 2025-08-05 | $11.94M 10-Q · filed 2025-08-05 | $17.71M derived: sum of 3 quarters · filed 2025-08-05 | $35.19M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $5.05M 10-Q · filed 2025-05-14 | $10.82M derived: sum of 2 quarters · filed 2025-05-14 | $28.30M derived: sum of 3 quarters · filed 2025-05-14 | $33.90M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $23.25M derived: sum of 2 quarters · filed 2025-03-06 | $28.85M derived: sum of 3 quarters · filed 2025-03-06 | $34.16M 10-K · filed 2025-03-06 |
| 2023-09-30 | $17.48M 10-Q · filed 2024-11-04 | $23.08M derived: sum of 2 quarters · filed 2024-11-04 | $28.39M 10-Q · filed 2024-11-04 | $32.57M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $5.60M 10-Q · filed 2024-08-08 | $10.91M 10-Q · filed 2024-08-08 | $15.09M derived: sum of 3 quarters · filed 2024-08-08 | $21.73M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.31M 10-Q · filed 2024-05-06 | $9.49M derived: sum of 2 quarters · filed 2024-05-06 | $16.13M derived: sum of 3 quarters · filed 2024-05-06 | $20.62M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $10.82M derived: sum of 2 quarters · filed 2024-03-07 | $15.31M derived: sum of 3 quarters · filed 2024-03-07 | $19.23M 10-K · filed 2024-03-07 |
| 2022-09-30 | $6.63M 10-Q · filed 2023-11-02 | $11.12M derived: sum of 2 quarters · filed 2023-11-02 | $15.04M 10-Q · filed 2023-11-02 | $15.76M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $4.49M 10-Q · filed 2023-08-04 | $8.41M 10-Q · filed 2023-08-04 | $9.12M derived: sum of 3 quarters · filed 2023-08-04 | $9.16M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $3.92M 10-Q · filed 2023-05-08 | $4.63M derived: sum of 2 quarters · filed 2023-05-08 | $4.67M derived: sum of 3 quarters · filed 2023-05-08 | $4.95M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $713.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $754.00K derived: sum of 2 quarters · filed 2023-03-09 | $1.03M derived: sum of 3 quarters · filed 2023-03-09 | $1.32M 10-K · filed 2023-03-09 |
| 2021-09-30 | $41.00K 10-Q · filed 2022-11-08 | $320.00K derived: sum of 2 quarters · filed 2022-11-08 | $606.00K 10-Q · filed 2022-11-08 | $857.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $279.00K 10-Q · filed 2022-08-09 | $565.00K 10-Q · filed 2022-08-09 | $816.00K derived: sum of 3 quarters · filed 2022-08-09 | $995.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $286.00K 10-Q · filed 2022-05-09 | $537.00K derived: sum of 2 quarters · filed 2022-08-09 | $716.00K derived: sum of 3 quarters · filed 2022-08-09 | $716.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $251.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $430.00K derived: sum of 2 quarters · filed 2022-08-09 | $430.00K derived: sum of 3 quarters · filed 2022-08-09 | $430.00K 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $179.00K 10-Q · filed 2021-11-09 | $179.00K derived: sum of 2 quarters · filed 2021-11-09 | $179.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |